The Pink Sheet | From EUA to Full Approval: CDER, CBER Still Developing Transition Plans

Cathy Burgess is quoted on how the U.S. FDA’s Center for Drug Evaluation and Research could potentially handle the expiration of COVID-19-related emergency use authorizations it has issued for drug products.